Oncogenic mutations of ALK kinase in neuroblastoma - PubMed (original) (raw)
. 2008 Oct 16;455(7215):971-4.
doi: 10.1038/nature07399.
Junko Takita, Young Lim Choi, Motohiro Kato, Miki Ohira, Masashi Sanada, Lili Wang, Manabu Soda, Akira Kikuchi, Takashi Igarashi, Akira Nakagawara, Yasuhide Hayashi, Hiroyuki Mano, Seishi Ogawa
Affiliations
- PMID: 18923524
- DOI: 10.1038/nature07399
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al. Nature. 2008.
Abstract
Neuroblastoma in advanced stages is one of the most intractable paediatric cancers, even with recent therapeutic advances. Neuroblastoma harbours a variety of genetic changes, including a high frequency of MYCN amplification, loss of heterozygosity at 1p36 and 11q, and gain of genetic material from 17q, all of which have been implicated in the pathogenesis of neuroblastoma. However, the scarcity of reliable molecular targets has hampered the development of effective therapeutic agents targeting neuroblastoma. Here we show that the anaplastic lymphoma kinase (ALK), originally identified as a fusion kinase in a subtype of non-Hodgkin's lymphoma (NPM-ALK) and more recently in adenocarcinoma of lung (EML4-ALK), is also a frequent target of genetic alteration in advanced neuroblastoma. According to our genome-wide scans of genetic lesions in 215 primary neuroblastoma samples using high-density single-nucleotide polymorphism genotyping microarrays, the ALK locus, centromeric to the MYCN locus, was identified as a recurrent target of copy number gain and gene amplification. Furthermore, DNA sequencing of ALK revealed eight novel missense mutations in 13 out of 215 (6.1%) fresh tumours and 8 out of 24 (33%) neuroblastoma-derived cell lines. All but one mutation in the primary samples (12 out of 13) were found in stages 3-4 of the disease and were harboured in the kinase domain. The mutated kinases were autophosphorylated and displayed increased kinase activity compared with the wild-type kinase. They were able to transform NIH3T3 fibroblasts as shown by their colony formation ability in soft agar and their capacity to form tumours in nude mice. Furthermore, we demonstrate that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK. We anticipate that our findings will provide new insights into the pathogenesis of advanced neuroblastoma and that ALK-specific kinase inhibitors might improve its clinical outcome.
Comment in
- Cancer: A ringleader identified.
Eng C. Eng C. Nature. 2008 Oct 16;455(7215):883-4. doi: 10.1038/455883a. Nature. 2008. PMID: 18923503 No abstract available.
Similar articles
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Janoueix-Lerosey I, et al. Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398. Nature. 2008. PMID: 18923523 - Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, Sanada M, Hiwatari M, Hayashi Y, Igarashi T, Ogawa S. Okubo J, et al. Oncogene. 2012 Nov 1;31(44):4667-76. doi: 10.1038/onc.2011.616. Epub 2012 Jan 16. Oncogene. 2012. PMID: 22249260 - The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC, McDermott R. Kelleher FC, et al. Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Eur J Cancer. 2010. PMID: 20451371 Review. - Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R. Passoni L, et al. Cancer Res. 2009 Sep 15;69(18):7338-46. doi: 10.1158/0008-5472.CAN-08-4419. Epub 2009 Sep 1. Cancer Res. 2009. PMID: 19723661 - [Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma].
Takita J, Ogawa S. Takita J, et al. Tanpakushitsu Kakusan Koso. 2009 May;54(6):742-7. Tanpakushitsu Kakusan Koso. 2009. PMID: 19462760 Review. Japanese. No abstract available.
Cited by
- A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Hamilton AK, et al. Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003. Epub 2024 Oct 24. Cancer Cell. 2024. PMID: 39454577 - Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.
Han M, Niu H, Duan F, Wang Z, Zhang Z, Ren H. Han M, et al. Front Oncol. 2024 Oct 10;14:1383805. doi: 10.3389/fonc.2024.1383805. eCollection 2024. Front Oncol. 2024. PMID: 39450262 Free PMC article. - Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Tomuleasa C, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w. Signal Transduct Target Ther. 2024. PMID: 39138146 Free PMC article. Review. - Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.
Sundaramoorthy S, Colombo DF, Sanalkumar R, Broye L, Balmas Bourloud K, Boulay G, Cironi L, Stamenkovic I, Renella R, Kuttler F, Turcatti G, Rivera MN, Mühlethaler-Mottet A, Bardet AF, Riggi N. Sundaramoorthy S, et al. JCI Insight. 2024 Jul 22;9(14):e169647. doi: 10.1172/jci.insight.169647. JCI Insight. 2024. PMID: 39133652 Free PMC article. - Advances in liquid biopsy in neuroblastoma.
Zhuo Z, Lin L, Miao L, Li M, He J. Zhuo Z, et al. Fundam Res. 2022 Aug 17;2(6):903-917. doi: 10.1016/j.fmre.2022.08.005. eCollection 2022 Nov. Fundam Res. 2022. PMID: 38933377 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials